Delving into the Latest Updates on [177Lu]-MNPR-101 with Synapse

Overview

Basic Info

Drug Type

Therapeutic radiopharmaceuticals

Synonyms

MNPR-101-PCTA-177Lu

Target

uPAR

Action

modulators

Mechanism

uPAR modulators(Urokinase plasminogen activator surface receptor modulators)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Bladder CancerColorectal CancerLung Cancer+ [5]

Inactive Indication-

Originator Organization

Monopar Therapeutics, Inc.

Active Organization

Monopar Therapeutics, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is an open-label, uncontrolled, multi-center, phase 1a MNPR-101-PCTA-177Lu dose-escalation study in patients with solid tumor cancers. Patients must have participated in the imaging study MNPR-101-D001 (actively recruiting, diagnostic study of MNPR-101-DFO*-89Zr).
* TITE-BOIN will be used to objectively determine dose increase, no dose change, or dose decrease for each group of two patients.
* The treatment period consists of two 12-week cycles. Patients will receive three equal fractions of MNPR-101-PCTA-177Lu with radioactivity ranging from 480-2240 MBq on each of Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (12 weeks after Cycle 1 Day 1).
* Patients will be followed for 12 weeks after their last dose of MNPR-101-PCTA-177Lu.
* Patients will be imaged at specific timepoints during the study.

Start Date08 Oct 2024

Sponsor / Collaborator

Monopar Therapeutics, Inc.

NCT06980519

/ AvailableNot Applicable

Treatment of Patients With Solid Tumor Cancers Via Intermediate-Size Patient Population Expanded Access Investigational New Drug (IND)

The purpose of this Expanded Access Program (EAP) is to allow use of the investigational therapeutic agent, MNPR-101-PCTA-177Lu, for treatment of urokinase plasminogen activator receptor (uPAR)-positive solid tumors identified via positron emission tomography / computed tomography (PET/CT) with investigational imaging agent MNPR-101-DFO*-89Zr.

Start Date-

Sponsor / Collaborator

Monopar Therapeutics, Inc.

100 Clinical Results associated with [177Lu]-MNPR-101

Login to view more data

100 Translational Medicine associated with [177Lu]-MNPR-101

Login to view more data

100 Patents (Medical) associated with [177Lu]-MNPR-101

Login to view more data

100 Deals associated with [177Lu]-MNPR-101

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024
Colorectal Cancer	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024
Lung Cancer	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024
Ovarian Cancer	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024
Pancreatic Cancer	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024
Stomach Cancer	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024
Triple Negative Breast Cancer	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024
Urothelial Carcinoma of the Urinary Bladder	Phase 1	Australia	Monopar Therapeutics, Inc.	08 Oct 2024